Ontology type: schema:ScholarlyArticle
2005-01
AUTHORSToshiyuki Matstji, Toshihiro Sakurai, Tsuneyoshi Yao
ABSTRACTIn Japan, nutritional therapy as both a primary and as a secondary treatment is widely used for Crohn’s disease (CD). The rationale for its use is based on a variety of reasons. The first is its ability to induce remission and to ameliorate the activity of intestinal lesions in the short term by enterai (EN) or by parenteral nutritional therapy in which overexpressions of chemokine receptors in an active stage are decreased significantly in the remission stage. Second is its ability to maintain remission over the long term through home-based enterai nutrition in which tube feeding during the nighttime is encouraged. Third is its ability to reduce the steroid dosage over the period of a long-term treatment course. However, several disadvantages of this therapy such as unpalatability and sluggish effect have been pointed out. Several studies have attempted to resolve this issue and determine the best components of EN, especially in fat composition. Some data have been suggestive of too much long-chained fatty acid having a hazardous effect on EN’s clinical efficacy because it works as a precursor of inflammatory prostaglandins. Our recent data show that medium-chained triglyceride did not have such a hazardous effect on clinical efficacy. Several studies suggested that the patient factors that were resistant to inducing remission in the short term were a long period of suffering CD, a high activity (on Crohn’s Disease Activity Index, CDAI), hemorrhagic colitis, and colitis with marked cobblestoning. Japanese guidelines for the treatment of CD recommended nutritional therapy as a first-line therapy and as a maintenance therapy after inducing remission. This treatment policy has led to Japanese CD patients having lower mortality rates than that of patients who do not receive EN. If this therapy could be combined with other drug therapies, including strong immunosuppressants, treatment strategies would be improved over those we have at present. More... »
PAGES25-31
http://scigraph.springernature.com/pub.10.1007/bf02990575
DOIhttp://dx.doi.org/10.1007/bf02990575
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1020737306
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/15902960
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adrenal Cortex Hormones",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Crohn Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Dietary Fats",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Enteral Nutrition",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Japan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Practice Guidelines as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Remission Induction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Time Factors",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan",
"id": "http://www.grid.ac/institutes/grid.413918.6",
"name": [
"Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan"
],
"type": "Organization"
},
"familyName": "Matstji",
"givenName": "Toshiyuki",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan",
"id": "http://www.grid.ac/institutes/grid.413918.6",
"name": [
"Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan"
],
"type": "Organization"
},
"familyName": "Sakurai",
"givenName": "Toshihiro",
"id": "sg:person.014200712642.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200712642.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan",
"id": "http://www.grid.ac/institutes/grid.413918.6",
"name": [
"Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan"
],
"type": "Organization"
},
"familyName": "Yao",
"givenName": "Tsuneyoshi",
"id": "sg:person.012137076572.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012137076572.03"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1111/j.1572-0241.2000.01527.x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014529196",
"https://doi.org/10.1111/j.1572-0241.2000.01527.x"
],
"type": "CreativeWork"
}
],
"datePublished": "2005-01",
"datePublishedReg": "2005-01-01",
"description": "In Japan, nutritional therapy as both a primary and as a secondary treatment is widely used for Crohn\u2019s disease (CD). The rationale for its use is based on a variety of reasons. The first is its ability to induce remission and to ameliorate the activity of intestinal lesions in the short term by enterai (EN) or by parenteral nutritional therapy in which overexpressions of chemokine receptors in an active stage are decreased significantly in the remission stage. Second is its ability to maintain remission over the long term through home-based enterai nutrition in which tube feeding during the nighttime is encouraged. Third is its ability to reduce the steroid dosage over the period of a long-term treatment course. However, several disadvantages of this therapy such as unpalatability and sluggish effect have been pointed out. Several studies have attempted to resolve this issue and determine the best components of EN, especially in fat composition. Some data have been suggestive of too much long-chained fatty acid having a hazardous effect on EN\u2019s clinical efficacy because it works as a precursor of inflammatory prostaglandins. Our recent data show that medium-chained triglyceride did not have such a hazardous effect on clinical efficacy. Several studies suggested that the patient factors that were resistant to inducing remission in the short term were a long period of suffering CD, a high activity (on Crohn\u2019s Disease Activity Index, CDAI), hemorrhagic colitis, and colitis with marked cobblestoning. Japanese guidelines for the treatment of CD recommended nutritional therapy as a first-line therapy and as a maintenance therapy after inducing remission. This treatment policy has led to Japanese CD patients having lower mortality rates than that of patients who do not receive EN. If this therapy could be combined with other drug therapies, including strong immunosuppressants, treatment strategies would be improved over those we have at present.",
"genre": "article",
"id": "sg:pub.10.1007/bf02990575",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1009747",
"issn": [
"0944-1174",
"1435-5922"
],
"name": "Journal of Gastroenterology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "Suppl 16",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "40"
}
],
"keywords": [
"Crohn's disease",
"nutritional therapy",
"clinical efficacy",
"treatment of CD",
"parenteral nutritional therapy",
"first-line therapy",
"long-term treatment course",
"lower mortality rate",
"Japanese CD patients",
"medium-chain triglycerides",
"steroid dosage",
"maintenance therapy",
"tube feeding",
"CD patients",
"remission stage",
"patient factors",
"treatment course",
"drug therapy",
"intestinal lesions",
"enterai nutrition",
"chemokine receptors",
"treatment strategies",
"inflammatory prostaglandins",
"hemorrhagic colitis",
"Japanese guidelines",
"strong immunosuppressant",
"remission",
"mortality rate",
"treatment policy",
"therapy",
"disease",
"fat composition",
"active stage",
"short term",
"patients",
"hazardous effects",
"recent data",
"efficacy",
"fatty acids",
"treatment",
"long term",
"variety of reasons",
"colitis",
"secondary treatment",
"immunosuppressants",
"prostaglandins",
"lesions",
"triglycerides",
"receptors",
"period",
"activity",
"effect",
"long period",
"study",
"nutrition",
"dosage",
"overexpression",
"guidelines",
"feeding",
"ability",
"stage",
"course",
"rationale",
"data",
"factors",
"rate",
"high activity",
"Japan",
"acid",
"use",
"strategies",
"reasons",
"nighttime",
"variety",
"terms",
"disadvantages",
"sluggish effect",
"precursors",
"unpalatability",
"components",
"issues",
"policy",
"composition",
"best components"
],
"name": "Nutritional therapy for Crohn\u2019s disease in Japan",
"pagination": "25-31",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1020737306"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/bf02990575"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"15902960"
]
}
],
"sameAs": [
"https://doi.org/10.1007/bf02990575",
"https://app.dimensions.ai/details/publication/pub.1020737306"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:23",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_406.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/bf02990575"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02990575'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02990575'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02990575'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02990575'
This table displays all metadata directly associated to this object as RDF triples.
199 TRIPLES
22 PREDICATES
121 URIs
112 LITERALS
16 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/bf02990575 | schema:about | N1b43e1be077b4d57aca4626137594cc7 |
2 | ″ | ″ | N21712c8c3b084d32b57ce8c00b406339 |
3 | ″ | ″ | N23fedb41092a4c4985ce0c8fa14c6641 |
4 | ″ | ″ | N27564cf198974ca697bc0e3e194b026a |
5 | ″ | ″ | N3a29313b886246b1a1809fda07a2523a |
6 | ″ | ″ | N7e370cbf08f546b08454de683621f155 |
7 | ″ | ″ | N82cc40f771b843db95ddcea6faa7a253 |
8 | ″ | ″ | Nca03183f134b4c0291ab091d77f55eb1 |
9 | ″ | ″ | Nfc6dc844f05840ce864f38783b000eec |
10 | ″ | ″ | anzsrc-for:11 |
11 | ″ | ″ | anzsrc-for:1103 |
12 | ″ | schema:author | N9467ce06ee2f4f168b6a02c732c34f14 |
13 | ″ | schema:citation | sg:pub.10.1111/j.1572-0241.2000.01527.x |
14 | ″ | schema:datePublished | 2005-01 |
15 | ″ | schema:datePublishedReg | 2005-01-01 |
16 | ″ | schema:description | In Japan, nutritional therapy as both a primary and as a secondary treatment is widely used for Crohn’s disease (CD). The rationale for its use is based on a variety of reasons. The first is its ability to induce remission and to ameliorate the activity of intestinal lesions in the short term by enterai (EN) or by parenteral nutritional therapy in which overexpressions of chemokine receptors in an active stage are decreased significantly in the remission stage. Second is its ability to maintain remission over the long term through home-based enterai nutrition in which tube feeding during the nighttime is encouraged. Third is its ability to reduce the steroid dosage over the period of a long-term treatment course. However, several disadvantages of this therapy such as unpalatability and sluggish effect have been pointed out. Several studies have attempted to resolve this issue and determine the best components of EN, especially in fat composition. Some data have been suggestive of too much long-chained fatty acid having a hazardous effect on EN’s clinical efficacy because it works as a precursor of inflammatory prostaglandins. Our recent data show that medium-chained triglyceride did not have such a hazardous effect on clinical efficacy. Several studies suggested that the patient factors that were resistant to inducing remission in the short term were a long period of suffering CD, a high activity (on Crohn’s Disease Activity Index, CDAI), hemorrhagic colitis, and colitis with marked cobblestoning. Japanese guidelines for the treatment of CD recommended nutritional therapy as a first-line therapy and as a maintenance therapy after inducing remission. This treatment policy has led to Japanese CD patients having lower mortality rates than that of patients who do not receive EN. If this therapy could be combined with other drug therapies, including strong immunosuppressants, treatment strategies would be improved over those we have at present. |
17 | ″ | schema:genre | article |
18 | ″ | schema:inLanguage | en |
19 | ″ | schema:isAccessibleForFree | false |
20 | ″ | schema:isPartOf | N03a856d31a844d3c8425aa95147611c9 |
21 | ″ | ″ | Ne9ac7a9c72db4c97987a417a9c3e5459 |
22 | ″ | ″ | sg:journal.1009747 |
23 | ″ | schema:keywords | CD patients |
24 | ″ | ″ | Crohn's disease |
25 | ″ | ″ | Japan |
26 | ″ | ″ | Japanese CD patients |
27 | ″ | ″ | Japanese guidelines |
28 | ″ | ″ | ability |
29 | ″ | ″ | acid |
30 | ″ | ″ | active stage |
31 | ″ | ″ | activity |
32 | ″ | ″ | best components |
33 | ″ | ″ | chemokine receptors |
34 | ″ | ″ | clinical efficacy |
35 | ″ | ″ | colitis |
36 | ″ | ″ | components |
37 | ″ | ″ | composition |
38 | ″ | ″ | course |
39 | ″ | ″ | data |
40 | ″ | ″ | disadvantages |
41 | ″ | ″ | disease |
42 | ″ | ″ | dosage |
43 | ″ | ″ | drug therapy |
44 | ″ | ″ | effect |
45 | ″ | ″ | efficacy |
46 | ″ | ″ | enterai nutrition |
47 | ″ | ″ | factors |
48 | ″ | ″ | fat composition |
49 | ″ | ″ | fatty acids |
50 | ″ | ″ | feeding |
51 | ″ | ″ | first-line therapy |
52 | ″ | ″ | guidelines |
53 | ″ | ″ | hazardous effects |
54 | ″ | ″ | hemorrhagic colitis |
55 | ″ | ″ | high activity |
56 | ″ | ″ | immunosuppressants |
57 | ″ | ″ | inflammatory prostaglandins |
58 | ″ | ″ | intestinal lesions |
59 | ″ | ″ | issues |
60 | ″ | ″ | lesions |
61 | ″ | ″ | long period |
62 | ″ | ″ | long term |
63 | ″ | ″ | long-term treatment course |
64 | ″ | ″ | lower mortality rate |
65 | ″ | ″ | maintenance therapy |
66 | ″ | ″ | medium-chain triglycerides |
67 | ″ | ″ | mortality rate |
68 | ″ | ″ | nighttime |
69 | ″ | ″ | nutrition |
70 | ″ | ″ | nutritional therapy |
71 | ″ | ″ | overexpression |
72 | ″ | ″ | parenteral nutritional therapy |
73 | ″ | ″ | patient factors |
74 | ″ | ″ | patients |
75 | ″ | ″ | period |
76 | ″ | ″ | policy |
77 | ″ | ″ | precursors |
78 | ″ | ″ | prostaglandins |
79 | ″ | ″ | rate |
80 | ″ | ″ | rationale |
81 | ″ | ″ | reasons |
82 | ″ | ″ | recent data |
83 | ″ | ″ | receptors |
84 | ″ | ″ | remission |
85 | ″ | ″ | remission stage |
86 | ″ | ″ | secondary treatment |
87 | ″ | ″ | short term |
88 | ″ | ″ | sluggish effect |
89 | ″ | ″ | stage |
90 | ″ | ″ | steroid dosage |
91 | ″ | ″ | strategies |
92 | ″ | ″ | strong immunosuppressant |
93 | ″ | ″ | study |
94 | ″ | ″ | terms |
95 | ″ | ″ | therapy |
96 | ″ | ″ | treatment |
97 | ″ | ″ | treatment course |
98 | ″ | ″ | treatment of CD |
99 | ″ | ″ | treatment policy |
100 | ″ | ″ | treatment strategies |
101 | ″ | ″ | triglycerides |
102 | ″ | ″ | tube feeding |
103 | ″ | ″ | unpalatability |
104 | ″ | ″ | use |
105 | ″ | ″ | variety |
106 | ″ | ″ | variety of reasons |
107 | ″ | schema:name | Nutritional therapy for Crohn’s disease in Japan |
108 | ″ | schema:pagination | 25-31 |
109 | ″ | schema:productId | N09b3204574214f358d6a199dbd3b9623 |
110 | ″ | ″ | N4a38758601644082b586d9731bc73f8e |
111 | ″ | ″ | Nbc3cb6e83fe9496386a2eed9fc33cc95 |
112 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1020737306 |
113 | ″ | ″ | https://doi.org/10.1007/bf02990575 |
114 | ″ | schema:sdDatePublished | 2022-05-20T07:23 |
115 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
116 | ″ | schema:sdPublisher | Nc45421bf6b0d4e849875f86137b8861a |
117 | ″ | schema:url | https://doi.org/10.1007/bf02990575 |
118 | ″ | sgo:license | sg:explorer/license/ |
119 | ″ | sgo:sdDataset | articles |
120 | ″ | rdf:type | schema:ScholarlyArticle |
121 | N03a856d31a844d3c8425aa95147611c9 | schema:issueNumber | Suppl 16 |
122 | ″ | rdf:type | schema:PublicationIssue |
123 | N09b3204574214f358d6a199dbd3b9623 | schema:name | doi |
124 | ″ | schema:value | 10.1007/bf02990575 |
125 | ″ | rdf:type | schema:PropertyValue |
126 | N15d79af6375c44a7b31d7ce3b10883a2 | schema:affiliation | grid-institutes:grid.413918.6 |
127 | ″ | schema:familyName | Matstji |
128 | ″ | schema:givenName | Toshiyuki |
129 | ″ | rdf:type | schema:Person |
130 | N1b43e1be077b4d57aca4626137594cc7 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
131 | ″ | schema:name | Japan |
132 | ″ | rdf:type | schema:DefinedTerm |
133 | N21712c8c3b084d32b57ce8c00b406339 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
134 | ″ | schema:name | Remission Induction |
135 | ″ | rdf:type | schema:DefinedTerm |
136 | N23fedb41092a4c4985ce0c8fa14c6641 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
137 | ″ | schema:name | Dietary Fats |
138 | ″ | rdf:type | schema:DefinedTerm |
139 | N27564cf198974ca697bc0e3e194b026a | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
140 | ″ | schema:name | Enteral Nutrition |
141 | ″ | rdf:type | schema:DefinedTerm |
142 | N3a29313b886246b1a1809fda07a2523a | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
143 | ″ | schema:name | Humans |
144 | ″ | rdf:type | schema:DefinedTerm |
145 | N4a38758601644082b586d9731bc73f8e | schema:name | dimensions_id |
146 | ″ | schema:value | pub.1020737306 |
147 | ″ | rdf:type | schema:PropertyValue |
148 | N6e1718fbb9ea4b50b0de299a744df6bf | rdf:first | sg:person.012137076572.03 |
149 | ″ | rdf:rest | rdf:nil |
150 | N7e370cbf08f546b08454de683621f155 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
151 | ″ | schema:name | Practice Guidelines as Topic |
152 | ″ | rdf:type | schema:DefinedTerm |
153 | N82cc40f771b843db95ddcea6faa7a253 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
154 | ″ | schema:name | Adrenal Cortex Hormones |
155 | ″ | rdf:type | schema:DefinedTerm |
156 | N9467ce06ee2f4f168b6a02c732c34f14 | rdf:first | N15d79af6375c44a7b31d7ce3b10883a2 |
157 | ″ | rdf:rest | Nb4ad47cd54fd40b190357e30c700d65c |
158 | Nb4ad47cd54fd40b190357e30c700d65c | rdf:first | sg:person.014200712642.82 |
159 | ″ | rdf:rest | N6e1718fbb9ea4b50b0de299a744df6bf |
160 | Nbc3cb6e83fe9496386a2eed9fc33cc95 | schema:name | pubmed_id |
161 | ″ | schema:value | 15902960 |
162 | ″ | rdf:type | schema:PropertyValue |
163 | Nc45421bf6b0d4e849875f86137b8861a | schema:name | Springer Nature - SN SciGraph project |
164 | ″ | rdf:type | schema:Organization |
165 | Nca03183f134b4c0291ab091d77f55eb1 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
166 | ″ | schema:name | Time Factors |
167 | ″ | rdf:type | schema:DefinedTerm |
168 | Ne9ac7a9c72db4c97987a417a9c3e5459 | schema:volumeNumber | 40 |
169 | ″ | rdf:type | schema:PublicationVolume |
170 | Nfc6dc844f05840ce864f38783b000eec | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
171 | ″ | schema:name | Crohn Disease |
172 | ″ | rdf:type | schema:DefinedTerm |
173 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
174 | ″ | schema:name | Medical and Health Sciences |
175 | ″ | rdf:type | schema:DefinedTerm |
176 | anzsrc-for:1103 | schema:inDefinedTermSet | anzsrc-for: |
177 | ″ | schema:name | Clinical Sciences |
178 | ″ | rdf:type | schema:DefinedTerm |
179 | sg:journal.1009747 | schema:issn | 0944-1174 |
180 | ″ | ″ | 1435-5922 |
181 | ″ | schema:name | Journal of Gastroenterology |
182 | ″ | schema:publisher | Springer Nature |
183 | ″ | rdf:type | schema:Periodical |
184 | sg:person.012137076572.03 | schema:affiliation | grid-institutes:grid.413918.6 |
185 | ″ | schema:familyName | Yao |
186 | ″ | schema:givenName | Tsuneyoshi |
187 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012137076572.03 |
188 | ″ | rdf:type | schema:Person |
189 | sg:person.014200712642.82 | schema:affiliation | grid-institutes:grid.413918.6 |
190 | ″ | schema:familyName | Sakurai |
191 | ″ | schema:givenName | Toshihiro |
192 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200712642.82 |
193 | ″ | rdf:type | schema:Person |
194 | sg:pub.10.1111/j.1572-0241.2000.01527.x | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1014529196 |
195 | ″ | ″ | https://doi.org/10.1111/j.1572-0241.2000.01527.x |
196 | ″ | rdf:type | schema:CreativeWork |
197 | grid-institutes:grid.413918.6 | schema:alternateName | Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan |
198 | ″ | schema:name | Department of Gastroenterology, Fukuoka University Chikushi Hospital, 377-1 Chikushino, Zokumyouin, 818-8502, Chikushino, Japan |
199 | ″ | rdf:type | schema:Organization |